Stock Fundamentals

Company Information

Company Name
Precigen Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US74017N1054
CIK: 0001356090
CUSIP: 74017N105
Currency: USD
Full Time Employees: 160
Phone: 301 556 9900
Fiscal Year End: December
IPO Date: Aug 08, 2013
Description:

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Address:

20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876

Directors & Officers

Name Title Year Born
Mr. Randal J. Kirk J.D. Executive Chairman 1953
Dr. Helen Sabzevari MPH, Ph.D. President, CEO & Director 1962
Mr. Harry Thomasian Jr. Chief Financial Officer 1962
Mr. Rutul R. Shah Chief Operating Officer 1981
Mr. Donald P. Lehr J.D., Ph.D. Chief Legal Officer & Corporate Secretary 1975
Mr. Phil Tennant Chief Commercial Officer 1970
Mr. Steven M. Harasym VP & Head of Investor Relations NA
Dr. Douglas E. Brough Ph.D. Senior VP & Head of Research 1955
Dr. Bryan T. Butman Ph.D. Senior VP & Head of CMC 1953
Dr. Amy R. Lankford Ph.D. Senior VP & Head of Clinical Operations and Regulatory Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 30, 2026 Randal J Kirk N/A Sale 4.77M $3.30 $15.75M
Dec 22, 2025 Randal J Kirk N/A Sale 1.90M $4.18 $7.94M
Nov 21, 2025 Randal J Kirk N/A Sale 937.31K $3.83 $3.59M
Nov 20, 2025 Randal J Kirk N/A Sale 942.83K $4.08 $3.85M
Nov 19, 2025 Randal J Kirk N/A Sale 1.09M $4.47 $4.86M
Sep 30, 2025 Jeffrey B Kindler N/A Sale 106.84K $3.38 $361.11K
Sep 30, 2025 Randal J Kirk N/A Sale 1.81M $3.41 $6.17M
Sep 29, 2025 Jeffrey B Kindler N/A Sale 67.52K $3.60 $243.08K
Sep 26, 2025 Harry Jr. Thomasian N/A Purchase 2.93K $3.42 $10.03K
Sep 26, 2025 Rutul R Shah N/A Purchase 2.00K $3.40 $6.80K
Sep 25, 2025 Harry Jr. Thomasian N/A Purchase 8.28K $3.62 $29.99K
Sep 19, 2025 Randal J Kirk N/A Sale 3.60M $3.68 $13.24M
Sep 18, 2025 Randal J Kirk N/A Sale 1.40M $3.86 $5.42M
Sep 04, 2025 Nancy H Agee N/A Purchase 15.00K $4.60 $69.00K
Aug 28, 2025 Nancy H Agee N/A Purchase 10.65K $4.65 $49.50K
Aug 19, 2025 Nancy H Agee N/A Purchase 15.36K $3.20 $49.15K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Patients Capital Management LLC 17.82M Mar 31, 2026 5.00% $2.52 -4.58%
BlackRock Inc 15.22M Mar 31, 2026 4.27% $0.00 0.85%
State Street Corp 10.89M Mar 31, 2026 3.05% $0.00 0.60%
Vanguard Group Inc 10.48M Dec 31, 2025 2.94% $0.00 17.19%
Vanguard Capital Management, LLC 7.15M Mar 31, 2026 2.01% $0.00 0.00%
Diametric Capital, LP 6.80M Mar 31, 2026 1.91% $6.84 76.81%
Point72 Asset Management, L.P. 6.64M Mar 31, 2026 1.86% $0.03 -51.59%
TANG CAPITAL MANAGEMENT LLC 6.42M Mar 31, 2026 1.80% $1.26 14.24%
Geode Capital Management, LLC 4.61M Mar 31, 2026 1.29% $0.00 3.39%
Occam Crest Management L.P. 4.27M Mar 31, 2026 1.20% $10.03 21.91%
Iridian Asset Management LLC 3.59M Mar 31, 2026 1.01% $5.64 -0.21%
Boxer Capital Management, LLC 3.50M Mar 31, 2026 0.98% $1.78 154.55%
The Goldman Sachs Group Inc 3.35M Mar 31, 2026 0.94% $0.00 54.12%
Citadel Advisors Llc 2.70M Mar 31, 2026 0.76% $0.00 -16.84%
Franklin Resources Inc 2.63M Mar 31, 2026 0.74% $0.00 462.73%
Morgan Stanley - Brokerage Accounts 2.41M Mar 31, 2026 0.68% $0.00 -24.40%
Vanguard Portfolio Management, LLC 2.12M Mar 31, 2026 0.59% $0.00 0.00%
FMR Inc 2.00M Mar 31, 2026 0.56% $0.00 -57.04%
Jane Street Group LLC 1.82M Mar 31, 2026 0.51% $0.00 0.00%
Northern Trust Corp 1.61M Mar 31, 2026 0.45% $0.00 2.07%

Shares Statistics

Shares Outstanding: 356.51M
Shares Float: 189.46M
% Insiders: 1,370.60%
% Institutions: 7,109.20%
Short % Float: 20.79%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Patient Opportunity C 12.90M 3.62% ▼ 7.97% Mar 31, 2026
2 State Street® SPDR® S&P® Biotech ETF 6.64M 1.86% ▼ 0.61% May 31, 2026
3 Vanguard Total Stock Mkt Idx Inv 5.00M 1.40% ▲ 0.00% Apr 30, 2026
4 iShares Russell 2000 ETF 4.30M 1.21% ▲ 0.93% May 29, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 1.99M 0.56% ▲ 0.52% Apr 30, 2026
6 Fidelity Small Cap Index 1.77M 0.50% ▲ 0.23% Mar 31, 2026
7 iShares Russell 2000 Growth ETF 1.37M 0.38% ▼ 0.65% May 29, 2026
8 Fidelity Small Cap Growth 1.30M 0.36% ▼ 27.92% Mar 31, 2026
9 First Trust Small Cap Gr AlphaDEX® ETF 1.28M 0.36% ▲ 0.58% May 31, 2026
10 Russell 2000 Equity Index Fund B 1.12M 0.31% ▲ 16.50% Dec 31, 2025

Valuation Metrics

Enterprise Value: $1.63B
Trailing P/E: 0.00
Forward P/E: 222.22

Financial Highlights

Market Cap: $1.59B
EBITDA: $-86.33M
Book Value: $0.06
Earnings/Share: $-1.21
Profit Margin: 0.00%
Operating Margin: -25.78%
ROA (TTM): -42.07%
ROE (TTM): -1,145.42%
Revenue (TTM): $31.60M
Revenue/Share (TTM): $0.10
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 1,633.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.09x 4.51x 0.87x -27.57x -0.39x
2024-12-31 4.76x 0.02x 0.73x -22,504.83x -0.01x
2023-12-31 2.99x 0.01x 0.22x -213.16x -0.01x
2022-12-31 1.50x 0.35x 0.42x -11.18x -0.71x
2021-12-31 4.52x 1.72x 0.70x -4.90x -2.37x
2020-12-31 3.54x 2.60x 0.79x -4.69x -2.57x
2019-12-31 1.91x 3.10x 0.84x -4.74x -3.23x
2018-12-31 4.64x 0.58x 0.47x -59.27x -0.61x
2017-12-31 1.92x 0.02x 0.35x -225.68x -0.08x
2016-12-31 3.33x 0.02x 0.40x -145.37x -0.05x
2015-12-31 4.27x 0.01x 0.28x -118.06x -0.13x
2014-12-31 3.68x 0.03x 0.29x -105.05x -0.17x
2013-12-31 9.46x 0.00x 0.19x -411.51x 0.00x
2012-12-31 0.81x 0.00x 3.12x -1,318.54x 0.00x
2011-12-31 1.31x 0.00x 2.93x -450.42x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PGEN.US!